Protease-Resistant Peptide Shuttles for Blood-Brain Barrier Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering substances to the brain across the blood-brain barrier (BBB) are limited due to the barrier's selective permeability and efflux pumps, making it difficult to treat neurodegenerative diseases and other central nervous system disorders effectively, as many therapeutic compounds cannot cross the BBB on their own and existing delivery methods are invasive or have side effects.
Innovation Solution
Development of peptide shuttle compounds, such as PWVPSWMPPRHT and GPWVPSWMPPRHT, which utilize receptor-mediated transcytosis to transport therapeutic and diagnostic agents across the BBB, offering improved stability and permeability compared to previous peptides like THRPPMWSPVWP, allowing for efficient delivery of substances that cannot cross the BBB independently.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If passive diffusion is used to cross the BBB, then lipophilic compounds can cross the barrier, but the process is highly selective and regulated by efflux pumps that prevent accumulation of substances
Solution Approach 1:
The patent uses peptide shuttles as intermediary carriers that bind to therapeutic compounds and facilitate their transport across the BBB through receptor-mediated transcytosis. The peptide acts as a mediator that overcomes the selectivity limitations of passive diffusion by utilizing specific transport pathways ( transferrin receptor, insulin receptor, or amino acid transporter-mediated endocytosis) to deliver cargo that would otherwise be excluded by efflux pumps.
2Reliability
If invasive administration methods are used to deliver drugs to the brain, then delivery can be achieved, but the methods imply risk of infection and toxicity and require qualified personnel
Solution Approach 1:
The peptide shuttle serves as a non-invasive intermediary that enables drug delivery through natural BBB transport mechanisms. By conjugating therapeutic agents to peptides that recognize and bind to BBB transport receptors, the system achieves effective brain delivery without requiring invasive procedures such as intracranial injection or osmotic disruption, thereby eliminating associated infection and toxicity risks.
Solution Approach 2:
The patent replaces mechanical/invasive delivery methods with a biochemical mechanism. Instead of physically disrupting the BBB or injecting directly into the brain, the system uses receptor-ligand interactions and biological transport processes (endocytosis, transcytosis) to achieve drug delivery, substituting a safe biochemical pathway for a harmful mechanical one.
3Reliability
If drug modification is performed to enable BBB crossing, then compounds can cross the barrier, but irreversible modifications may alter drug activity and bioreversible modifications require enzymatic or chemical processes to recover the active drug
Solution Approach 1:
Instead of modifying the therapeutic drug's chemical structure to enable BBB crossing, the patent uses a peptide shuttle as an intermediary carrier. The drug remains unchanged and retains its full activity, while the peptide carrier handles the BBB transport function. This separates the delivery function from the therapeutic function, avoiding the need for irreversible or bioreversible drug modifications.
4Productivity
If peptide shuttles are used to transport substances across the BBB, then delivery efficiency is improved, but the peptides need enhanced stability against proteases in the blood
Solution Approach 1:
The patent employs D-amino acids instead of L-amino acids in the peptide sequence. This parameter change in stereochemistry confers protease resistance while maintaining the peptide's ability to interact with BBB transport receptors. The D-amino acid configuration alters the peptide's physical and chemical properties to enhance stability in the bloodstream without compromising its transport function.
Solution Approach 2:
The patent creates composite peptide structures that combine multiple functional elements: D-amino acid residues for protease resistance, specific sequence motifs for receptor recognition, and conjugation sites for cargo attachment. This composite design integrates stability and functionality into a single molecular entity that can withstand blood circulation while efficiently delivering cargo across the BBB.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptide shuttle compounds demonstrate enhanced ability to transport therapeutic and diagnostic agents into the brain, providing improved delivery efficiency and stability, reducing the need for invasive methods and minimizing side effects, thus enhancing treatment options for brain-related disorders.
Implementation Method 1
peptide shuttle compounds, such as PWVPSWMPPRHT and GPWVPSWMPPRHT, which utilize receptor-mediated transcytosis to transport therapeutic and diagnostic agents across the BBB
Data Source
AI summary
The peptides of formula (I) R1-(X)K-P-Y, where: R1 is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from H, CH3C(=O)-, and maleimide;X is a biradical selected from-NH-(CH2)r- C(=O)-, -C(=O)-(CH2)r-C(=O)-, -S(CH2)r-, -S-(CH2)r-C(=O)-, -O-(CH2)r-, -S-CH2-CH(NH2 )-C(=O)-, -O-(CH2)r-C(=O)-, -(CH2)r-C(=O)-, -NH-O-CH2-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-, -(CH2)r-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-, and -NH-(CH2)r-CH(NHC(=O)CH2NH2)-C(=O)-; r is 1-5; P is a biradical of an amino acid sequence comprising the sequence D-Pro-D-Trp- D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1); Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is selected from -NH2, -OH, -OR2and -NHR2; R2is a radical selected from (C1-C6)-alkyl and (CH2)2-NH-C(=O)-CH2-O-NH2; k is 0-2; m is 0-1; with the proviso that when the biradical X is -C(=O)(CH2)rC(=O)-, then R1 is H; when the N of the amino acid of the sequence P to which is attached the biradical X is a biradical -NH-, then m is 1, and when is a biradical -N-, then m is 0; and when R1 is maleimide then the biradical X is -C(=O)-(CH2)r-C(=O)-,-CH(NH2)-C(=O)-, -(CH2)r-C(=O)-, and -(CH2)r-C(=O)-NH-(CH2)r -CH(NH2)-C(=O)-. The peptides are useful as shuttles through the blood brain barrier (BBB). The constructions BBB-shuttle-cargo, being the cargo of a biologically active substance or for use in a diagnostic method, are useful in therapy and diagnosis.